invest summari despit report ep beat lower
guidanc driven headwind rx busi compani
expect sell merg separ although headlin
concern still like stock believ lot valu
unlock sharehold therefor multipl expans upward
earn revis drive share higher view
share trade intra-day
posit quarter support thesi consumer-fac
busi achiev sale compris greater
consolid sale chci realiz sale increas
yoy net sale decreas constant currenc basi chci
deliv adjust oper margin rx segment realiz
sale deliv adjust oper margin
well oper margin peer repurchas
share today announc enter
agreement subsidiari merck cover pursu
regulatori approv non-prescript over-the-counter nasonex nasal spray nasonex
current avail rx annual rx brand gener sale ltm
end june
report ep factset consensu
higher estim despit beat decreas
ep guidanc factset consensu
primarili due lower expect perform rx segment
shortfal new launch coupl challeng market
dynam expect carri forward drove decreas
ep today also announc board approv plan separ
rx busi anticip street time
board consid value-enhanc option separ sale merger
updat financi model decreas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk posit invest thesi price target
gener drug price stabil goe downsid risk
entir gener industri custom consolid creat greater leverag buy
consortium extract price concess gener compani
gener consolid may make harder compet small mid-siz
gener compani need consolid stay competit market custom
increas buy power competitor get bigger stay
could make hard compet industri
competit perrigo over-the-counter product europ could neg effect
market share price could make hard meet financi
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario estim likelihood share price
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casegrow chc sale industryomega turnaround better expecteddebt paydown better expectednew launch better expectedflea tick cough cold allergi season better scenario casegrow chc sale industryomega turnaround in-lin expectationsdebt paydown in-lin expectationsnew launch in-lin expectationsflea tick cough cold allergi season in-lin scenario casegrow chc sale industryomega turnaround expectationsdebt paydown expectationsnew launch expectationsflea tick cough cold allergi season scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot gross sg cost manag chca oper oper non oper pre-tax tax net averag util balanc sheet flexibl repurchas share quarter oper cantor fitzgerald research compani estim exhibit catalyst event calendar
datedriverupcom comprehens updat via confer dm pend approv gener per hfalaunch per settlement agreement singl entityresolv excipi issu re-launch per settlement brimonidin topic gel stay separ rx stay expiresearli stay foam stay lotion stay expir spray stay launch gener launch gener per settlementsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
perrigocantor mm except per share amount guidancemidpointestimatesnet net net expens pre-tax effect tax tax dilut ep share healthcar healthcar cantor fitzgerald research compani expect report dilut ep rang expect report oper incom rang expect report pre-tax incom expect report effect tax rate expect report tax expens expect adjust oper margin chca chci updat adjust ep guidanc due rx includ perform key product delay gproair scopolamin anim health/input cost chca fx translat chci repurchas expect new product sale total sale chci sale slightli lower organ basi due order ship exlud impact anim health busi net sale guidanc chca includ growth yoy driven over-the-counter infant nutrit guidanc includ loss partner product anim health impact growth chci expect organ constant currenc lower guidanc rx due proair longer expect launch adjust ep product delay includ authorizedgener scopolamin suppli disrupt longer anticip relaunch product greater price headwind anticip guidanc includ price eros assumpt consist expect rx adjust oper incom realiz due time new product regard whether year difficult comp due big flu season last year flu season effect rather one
exhibit incom statement analysi
million except ep compound-annual-growth-rate year end decemb incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnminterest cantor fitzgerald research compani report exclud acquisition-rel amort integration-rel charg restructur charg collabor payment omega acquisit relat expens equiti method invest loss relat tax effect exclud acquisition-rel amort collabor arrang payment restructur charg omega acquisit integration-rel expens increas litig accrual loss deriv incom transfer right agreement equiti method invest loss bridg fee extinguish debt weight averag effect share issu novemb financ omega acquisit escrow settlement relat sergeant acquisit integration-rel charg litig settlement million net write-up conting consider write-off ipr relat paddock rosemont acquisit transact cost extinguish debt intang asset impair loss sale invest acquisition-rel cost take-over defens fee tax effect non-gaap adjust exclud acquisition-rel amort expens oper result attribut held-for-sal vm india api busi acquisit integration-rel expens restructur relat fee intang asset goodwil impair charg relat bch segment loss equiti method invest loss earli extinguish debt tax effect non-gaap adjust non-oper chang defer tax item effect use tax attribut exclud amort expens relat acquir intang asset chang financi asset loss earli debt extinguish restructur charg impair charg oper result held sale busi tysabri royalti stream acquisit integr expens gains-to-loss ondivestitur unusu litig tax effect adjust exclud amort expens relat primarili acquir intang asset chang financi asset loss equiti invest acquisit charg conting consider adjust restructur charg termin benefit gain divestitur tax effect adjust exclud amort expens relat primarili acquir intang asset acquisition-rel charg conting consider adjust loss invest secur restructur charg termin benefit impair charg chang financi asset relat tax effect exhibit margin analysi
year end decemb cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb healthcar healthcar changeconsum healthcar healthcar cantor fitzgerald research compani report exhibit annual sale analysi
sale base new product anim healthallegra corticosteroid flonas disclos new product anim risk adjust new product healthcar acquisitionsgalpharm brand healthcar consum sale base paragraph iv gener piv piv piv hfa risk-adjust us paragraph iv rx cantor fitzgerald research compani reportsnot bold identifi paragraph iv opportun mean settl launch date pbm nutrit sale consum base busi end decemb
exhibit analysi
million decemb fiscal oper activitiesnet depreci net chang work capit net invest activitiespurchas acquisit intangibles- purchas proce market secur net financ activitiespay issuanc purchas treasuri stock- proce option employe stock purchases- dividend net /equiv balanc net /equiv balanc sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million decemb fiscal current intang sharehold equityaccount accru portion long term current term paid common stock treasuri sharehold liabil sharehold cantor fitzgerald research compani report august
diversifi store brand brand consum rx pharmaceut compani believ continu
market leader store brand brand consum drug forese futur
